Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56

Rodman & Renshaw analyst Michael G. King Jr. has initiated coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Buy rating. The firm has set a price target of $56 for the stock.